Omeros (OMER) Operating Income (2010 - 2026)
Omeros' (OMER) quarterly Operating Income came in at -$17.4 million in Q1 2026, up 50.18% year-on-year from -$11.6 million in Q1 2025, and up 40.09% quarter-over-quarter from -$29.1 million in Q4 2025.
Omeros (OMER) Operating Income (2010 - 2026) Analysis & Trends
Omeros has disclosed Operating Income across 17 years of filings, most recently posting -$17.4 million for Q1 2026.
- Operating Income for Q1 2026 came in at -$17.4 million, up 50.18% year-over-year; the trailing twelve-month figure through Mar 2026 was -$105.2 million (up 35.39% YoY), and the FY2025 annual result was -$122.8 million, up 26.45% from the prior year.
- Operating Income came in at -$17.4 million for Q1 2026 at Omeros, up from -$29.1 million in the prior quarter.
- In the past five years, Operating Income ranged from a high of -$17.4 million in Q1 2026 to a low of -$59.2 million in Q2 2024.
- The 5-year median for Operating Income is -$35.7 million (2023), against an average of -$37.4 million.
- Across the five-year window, Operating Income sank 44.64% in 2024 and jumped 50.18% in 2026, its largest moves.
- Omeros' Operating Income stood at -$40.1 million in 2022, then increased by 0.93% to -$39.8 million in 2023, then advanced by 16.12% to -$33.4 million in 2024, then rose by 12.81% to -$29.1 million in 2025, then soared by 40.09% to -$17.4 million in 2026.
- The last three Operating Income figures came in at -$17.4 million (Q1 2026), -$29.1 million (Q4 2025), and -$26.4 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -32.68 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -19.70 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.82 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -15.76 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.14 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -65.83 Mn |
| 10 | Omeros | 737.87 Mn | 602.55 Mn | 9.31 Mn | -17.42 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -17.42 Mn |
| Dec 31, 2025 | -29.08 Mn |
| Sep 30, 2025 | -26.39 Mn |
| Jun 30, 2025 | -32.35 Mn |
| Mar 31, 2025 | -34.97 Mn |
| Dec 31, 2024 | -33.36 Mn |
| Sep 30, 2024 | -35.41 Mn |
| Jun 30, 2024 | -59.16 Mn |
| Mar 31, 2024 | -39.03 Mn |
| Dec 31, 2023 | -39.77 Mn |
| Sep 30, 2023 | -48.15 Mn |
| Jun 30, 2023 | -40.90 Mn |
| Mar 31, 2023 | -35.71 Mn |
| Dec 31, 2022 | -40.14 Mn |
| Sep 30, 2022 | -50.77 Mn |
| Jun 30, 2022 | -37.44 Mn |
| Mar 31, 2022 | -35.05 Mn |
| Dec 31, 2021 | -42.89 Mn |
| Sep 30, 2021 | -39.83 Mn |
| Jun 30, 2021 | -45.61 Mn |